Revolution Medicines Chief Global Commercialization Officer Anthony Mancini disposes of common shares worth $347,000

By Public Technologies
  • Revolution Medicines Chief Global Commercialization Officer Anthony Mancini sold 1,764 common shares on Sep. 18, 2026 at USD 196.94.
  • Direct holdings fell to 40,352 shares following the transaction.
  • Sale executed under a Rule 10b5-1 trading plan adopted on June 11, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002124509-26-000010), on September 22, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk